Eli Lilly’s shares have surged 750 per cent over five years. Novo Nordisk’s are up about 360 per cent in the same period.

Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...

Men, baby boomers, and postgraduate-degree holders were among those most likely to say they wouldn’t choose medication over ...

WW International, known as WeightWatchers, saw its stock soar on new of its new compounded GLP-1 offering. But analysts say that's only a short-term solution to its ailing business.

Poor purity can cause patients to experience fever, chills, nausea, skin irritation, infections and low blood pressure.

WeightWatchers (WW) is trying to save its ailing business by betting on a market that threatens its very existence. The ...

That’s according to a new Employer Health Benefits Survey from KFF (formerly the Kaiser Family Foundation). But while a ...

WW stock popped after announcing a new compounded semaglutide product to benefit from the current shortage of weight loss ...

Unlike Ozempic, Wegovy is approved for weight management even though they both contain semaglutide. However, they do have ...

The novel GLP-1 receptor agonists will likely reduce the need for CABG and improve surgical outcomes, several argue.

Speakers from across the care continuum will discuss legislative updates, glucagon-like peptide-1 (GLP-1) use for weight management, and more at this year’s AMCP Nexus.

These two pharmaceutical giants are positioned for growth with their innovative diabetes and obesity treatments.